These results indicate that EphB4 is a predictor of the therapeutic efficacy of osimertinib and of the subsequent clinical outcomes of patients with EGFR mutation-positive lung adenocarcinoma. This evidence concerns the gene EPHB4 and lung adenocarcinoma.